Frontier Medicines

Frontier Medicines is a precision medicine company founded in 2018, with headquarters in South San Francisco, CA and Boston, MA, aiming to revolutionize patients' lives by targeting disease-causing proteins previously considered undruggable. The company has established a powerful platform utilizing technologies in chemoproteomics, covalent drug discovery, and machine learning to develop a pipeline of groundbreaking medicines. Their lead program focuses on addressing both the activated and inactive forms of KRAS G12C, a validated driver in several cancers. In 22 February 2024, Frontier Medicines secured an $80.00M Series C investment from notable investors including DCVC, MPM Capital, RA Capital Management, Deerfield Management, Droia Ventures, and Galapagos. With a primary focus on biopharma, biotechnology, and pharmaceuticals, the company's vision to advance science for the defeat of diseases, particularly cancer, reflects their commitment to pushing the boundaries of innovation.